Meaningful efficacy observed in slow-progressor subgroup; NfL biomarker improvements support potential for accelerated regulatory pathway SEOUL, South Korea, May 29, 2025 /PRNewswire/ -- ...

Neuronata-R®, an autologous bone marrow-derived mesenchymal stem cell (MSC) therapy for amyotrophic lateral sclerosis (ALS), ...

Discover how stem cells may help reduce acne scars by boosting collagen, improving skin texture, and speeding up healing—plus ...

Parkinson’s disease is a neurodegenerative disorder that causes a gradual loss of brain nerve cells, which produce a chemical ...

Researchers at the Abu Dhabi Stem Cells Centre are hopeful of a breakthrough in their work on a cure for Type 1 diabetes “in ...

Stem cells from donated placentas appear safe and may help ease secondary progressive MS, a small open-label Phase 1 clinical ...

The Global Stem Cell Therapy Market is set to witness a healthy growth rate of 20% by 2029. A favorable investment ...

Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that the ...

The FDA has granted Mesoblast’s stem cell therapy, Ryoncil (remestemcel-L), seven years of orphan drug exclusivity for the ...

a Phase 2 trial for subacute stroke reported that intravenous infusion of bone marrow–derived mononuclear cells was safe but had no effect on measures of neurological function. 9 A recent ...

Patients given Neuronata-R who progressed more slowly saw significant gains in CAFS, slower declines in ALSFRS-R scores, and ...